vs
Side-by-side financial comparison of Civeo Corp (CVEO) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
Civeo Corp is the larger business by last-quarter revenue ($161.6M vs $123.8M, roughly 1.3× NATURES SUNSHINE PRODUCTS INC). NATURES SUNSHINE PRODUCTS INC runs the higher net margin — 3.3% vs -4.0%, a 7.3% gap on every dollar of revenue. On growth, Civeo Corp posted the faster year-over-year revenue change (7.1% vs 4.7%). Civeo Corp produced more free cash flow last quarter ($14.5M vs $7.6M). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -1.4%).
The Civeo Corporation is an American accommodation services multinational corporation. It is a spin-off of Oil States International. It is a public company listed on the New York Stock Exchange.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
CVEO vs NATR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $161.6M | $123.8M |
| Net Profit | $-6.5M | $4.1M |
| Gross Margin | 22.7% | 72.5% |
| Operating Margin | -0.1% | 4.3% |
| Net Margin | -4.0% | 3.3% |
| Revenue YoY | 7.1% | 4.7% |
| Net Profit YoY | 58.1% | 1379.4% |
| EPS (diluted) | $-0.58 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $161.6M | $123.8M | ||
| Q3 25 | $170.5M | $128.3M | ||
| Q2 25 | $162.7M | $114.8M | ||
| Q1 25 | $144.0M | $113.2M | ||
| Q4 24 | $151.0M | $118.2M | ||
| Q3 24 | $176.3M | $114.6M | ||
| Q2 24 | $188.7M | $110.6M | ||
| Q1 24 | $166.1M | $111.0M |
| Q4 25 | $-6.5M | $4.1M | ||
| Q3 25 | $-455.0K | $5.3M | ||
| Q2 25 | $-3.3M | $5.3M | ||
| Q1 25 | $-9.8M | $4.7M | ||
| Q4 24 | $-15.4M | $-321.0K | ||
| Q3 24 | $-5.1M | $4.3M | ||
| Q2 24 | $8.2M | $1.3M | ||
| Q1 24 | $-5.1M | $2.3M |
| Q4 25 | 22.7% | 72.5% | ||
| Q3 25 | 25.7% | 73.3% | ||
| Q2 25 | 25.3% | 71.7% | ||
| Q1 25 | 20.4% | 72.1% | ||
| Q4 24 | 18.6% | 72.0% | ||
| Q3 24 | 21.4% | 71.3% | ||
| Q2 24 | 25.4% | 71.4% | ||
| Q1 24 | 21.5% | 71.2% |
| Q4 25 | -0.1% | 4.3% | ||
| Q3 25 | 4.1% | 7.0% | ||
| Q2 25 | 1.7% | 3.7% | ||
| Q1 25 | -3.8% | 5.4% | ||
| Q4 24 | -6.7% | 3.8% | ||
| Q3 24 | 0.0% | 4.6% | ||
| Q2 24 | 6.9% | 5.1% | ||
| Q1 24 | -1.1% | 4.2% |
| Q4 25 | -4.0% | 3.3% | ||
| Q3 25 | -0.3% | 4.2% | ||
| Q2 25 | -2.0% | 4.6% | ||
| Q1 25 | -6.8% | 4.2% | ||
| Q4 24 | -10.2% | -0.3% | ||
| Q3 24 | -2.9% | 3.8% | ||
| Q2 24 | 4.4% | 1.2% | ||
| Q1 24 | -3.1% | 2.1% |
| Q4 25 | $-0.58 | $0.23 | ||
| Q3 25 | $-0.04 | $0.30 | ||
| Q2 25 | $-0.25 | $0.28 | ||
| Q1 25 | $-0.72 | $0.25 | ||
| Q4 24 | $-1.04 | $-0.02 | ||
| Q3 24 | $-0.36 | $0.23 | ||
| Q2 24 | $0.56 | $0.07 | ||
| Q1 24 | $-0.35 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.4M | $93.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $174.4M | $161.6M |
| Total Assets | $477.4M | $261.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $93.9M | ||
| Q3 25 | $12.0M | $95.6M | ||
| Q2 25 | $14.6M | $81.3M | ||
| Q1 25 | $28.4M | $86.5M | ||
| Q4 24 | $5.2M | $84.7M | ||
| Q3 24 | $17.9M | $78.7M | ||
| Q2 24 | $7.4M | $68.7M | ||
| Q1 24 | $16.8M | $77.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $43.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $2.1M |
| Q4 25 | $174.4M | $161.6M | ||
| Q3 25 | $182.5M | $166.7M | ||
| Q2 25 | $209.4M | $163.7M | ||
| Q1 25 | $220.7M | $167.1M | ||
| Q4 24 | $236.4M | $161.0M | ||
| Q3 24 | $282.2M | $162.6M | ||
| Q2 24 | $297.4M | $156.4M | ||
| Q1 24 | $297.4M | $159.7M |
| Q4 25 | $477.4M | $261.1M | ||
| Q3 25 | $491.1M | $264.8M | ||
| Q2 25 | $508.8M | $254.9M | ||
| Q1 25 | $423.8M | $252.7M | ||
| Q4 24 | $405.1M | $240.9M | ||
| Q3 24 | $477.6M | $245.3M | ||
| Q2 24 | $483.2M | $235.8M | ||
| Q1 24 | $513.1M | $247.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.3M | $9.9M |
| Free Cash FlowOCF − Capex | $14.5M | $7.6M |
| FCF MarginFCF / Revenue | 8.9% | 6.1% |
| Capex IntensityCapex / Revenue | 3.0% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.3M | $9.9M | ||
| Q3 25 | $13.8M | $18.5M | ||
| Q2 25 | $-2.3M | $4.3M | ||
| Q1 25 | $-8.4M | $2.6M | ||
| Q4 24 | $9.5M | $12.2M | ||
| Q3 24 | $35.7M | $9.6M | ||
| Q2 24 | $32.4M | $1.3M | ||
| Q1 24 | $6.0M | $2.2M |
| Q4 25 | $14.5M | $7.6M | ||
| Q3 25 | $8.2M | $16.8M | ||
| Q2 25 | $-6.8M | $3.0M | ||
| Q1 25 | $-13.7M | $1.5M | ||
| Q4 24 | $1.8M | $10.0M | ||
| Q3 24 | $28.2M | $7.9M | ||
| Q2 24 | $27.0M | $-2.0M | ||
| Q1 24 | $372.0K | $-1.5M |
| Q4 25 | 8.9% | 6.1% | ||
| Q3 25 | 4.8% | 13.1% | ||
| Q2 25 | -4.2% | 2.6% | ||
| Q1 25 | -9.5% | 1.3% | ||
| Q4 24 | 1.2% | 8.5% | ||
| Q3 24 | 16.0% | 6.9% | ||
| Q2 24 | 14.3% | -1.9% | ||
| Q1 24 | 0.2% | -1.4% |
| Q4 25 | 3.0% | 1.9% | ||
| Q3 25 | 3.3% | 1.3% | ||
| Q2 25 | 2.8% | 1.2% | ||
| Q1 25 | 3.7% | 1.0% | ||
| Q4 24 | 5.1% | 1.9% | ||
| Q3 24 | 4.2% | 1.5% | ||
| Q2 24 | 2.8% | 3.0% | ||
| Q1 24 | 3.4% | 3.3% |
| Q4 25 | — | 2.41× | ||
| Q3 25 | — | 3.46× | ||
| Q2 25 | — | 0.81× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.21× | ||
| Q2 24 | 3.93× | 0.97× | ||
| Q1 24 | — | 0.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVEO
Segment breakdown not available.
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
